Den europeiske union -
norsk -
EMA (European Medicines Agency)
firmagon
ferring pharmaceuticals a/s - degarelix - prostata neoplasmer - endokrin terapi - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
Norge -
norsk -
Statens legemiddelverk
kandesartan farmagon 8 mg
farmagon - kandesartancileksetil - tablett - 8 mg
Norge -
norsk -
Statens legemiddelverk
kandesartan farmagon 16 mg
farmagon - kandesartancileksetil - tablett - 16 mg
Norge -
norsk -
Statens legemiddelverk
kandesartan-hydroklortiazid farmagon 16 mg / 12.5 mg
farmagon - kandesartancileksetil / hydroklortiazid - tablett - 16 mg / 12.5 mg
Norge -
norsk -
Statens legemiddelverk
anoro ellipta 55 mikrog / 22 mikrog
farmagon - umeklidiniumbromid / vilanteroltrifenatat - inhalasjonspulver, dosedispensert - 55 mikrog / 22 mikrog
Norge -
norsk -
Statens legemiddelverk
trulicity 1.5 mg
farmagon - dulaglutid - injeksjonsvæske, oppløsning - 1.5 mg
Norge -
norsk -
Statens legemiddelverk
incruse ellipta 55 mikrog
farmagon - umeklidiniumbromid - inhalasjonspulver, dosedispensert - 55 mikrog
Norge -
norsk -
Statens legemiddelverk
micardisplus 80 mg / 12.5 mg
farmagon - telmisartan / hydroklortiazid - tablett - 80 mg / 12.5 mg